Intellectual property offices of US/JP/AU/TW approved patent of LXP5268 for tumor treatment.
Patent NO. of US：US 10045962 B2
Patent NO. of JP：JP 6539345 B2
Patent NO. of AU：AU 2015335391 B2
Patent NO. of TW：I 621434
Results of preclinical experiment show that combined use of LXP 5268 and chemotherapeutic drugs can effectively and synergistically inhibit triple-negative breast cancer, and can significantly reduce the tumor volume.
In August 2021, a clinical trial of LXP5268 as an add-on neoadjuvant treatment in patients with triple-negative breast cancer (TNBC) has been conducted at the Central Taiwan Medical Center. The type of clinical trial is a Proof of concept (PoC) initiated by an Investigator-initiated the trial by the attending physician. The subject of the case was triple-negative breast cancer (TNBC).
We estimate the trial completion time will be in June 2023. The Design of clinical trial for LXP5268 will based on the result of PoC trial.